---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-211843"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:21:37.341446+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AlloVir Q2 net loss $44.6M; $126.5M July offering extends cash runway for Phase 3 trials

## Summary
- Net loss $44.6M ($0.69/sh) vs $37.6M ($0.60/sh) in Q2 2021; R&D expense rose to $31.4M.
- Cash $172.7M at June 30; July registered direct offering raised $126.5M to fund three Phase 3 posoleucel trials.
- Phase 2 multi-virus prevention final data expected year-end; Phase 2 BKV treatment topline in Q1 2023.
- Posoleucel granted EMA orphan designation for prevention; now holds three FDA RMAT designations.
- FY2022 operating expense guidance $130-145M, excluding stock-based compensation.

## SEC filing metadata
- accession: 0001193125-22-211843
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312522211843/0001193125-22-211843-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312522211843/d308599d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-211843
- JSON: https://secwatch.observer/filing/0001193125-22-211843.json
- Plain text: https://secwatch.observer/filing/0001193125-22-211843.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.